Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep 20;128(18):2498-504.
doi: 10.4103/0366-6999.164936.

Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas

Ping Zhou, Peng Liu, Sheng-Yu Zhou, Xiao-Hui He, Xiao-Hong Han, Yan Qin, Sheng Yang, Chang-Gong Zhang, Lin Gui, Jia-Rui Yao, Li-Ya Zhao, Shu-Xiang Zhang, Yan Sun, Yuan-Kai Shi  1
Affiliations

Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas

Ping Zhou et al. Chin Med J (Engl). .

Abstract

Background: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a promising approach for lymphomas. This study aimed to evaluate the effect of ifosfamide, cisplatin or carboplatin, and etoposide (ICE)-based regimen as a mobilization regimen on relapsed, refractory, or high-risk aggressive lymphoma.

Methods: From June 2001 to May 2013, patients with lymphomas who mobilized by ICE-based regimen for ASCT were analyzed in this retrospective study. The results of the autologous peripheral blood stem cells collection, toxicity, engraftment after ICE-based mobilization regimen were analyzed in this study. Furthermore, risk factors for overall survival (OS) and progression free survival (PFS) were evaluated by univariate analysis.

Results: The stem cells were mobilized using ICE-based regimen plus rituximab or ICE-based regimen alone in 12 patients and 54 patients, respectively. The results of stem cell mobilization were excellent. Ninety-seven percentages of the patients had the stem cell collection of at least 2.0 × 10 6 CD34 + cells/kg and 68% had at least 5 × 10 6 CD34 + cells/kg. Fifty-eight percentage of the patients experienced Grade 4 neutropenia, 20% developed febrile neutropenia, and only 12% had Grade 4 thrombocytopenia. At a median follow-up of 63.8 months, the 5-year PFS and OS were 64.4% and 75.3%, respectively.

Conclusion: ICE is a powerful regimen for stem cell mobilization in patients with lymphomas.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival (OS) and progression-free survival (PFS) of all the patients (n = 66).
Figure 2
Figure 2
Overall survival (OS) according to disease status at ICE-based regimen for assessable patients (n = 62).
Figure 3
Figure 3
Overall survival (OS) according to chemotherapy failure before mobilization (n = 66).
Figure 4
Figure 4
(a) Overall survival according to the time to first relapse before mobilization (n = 38); (b) Progression-free survival according to the time to first relapse before mobilization (n = 38).
See this image and copyright information in PMC

References

    1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540–5. - PubMed
    1. Baldomero H, Gratwohl M, Gratwohl A, Tichelli A, Niederwieser D, Madrigal A, et al. The EBMT activity survey 2009: Trends over the past 5 years. Bone Marrow Transplant. 2011;46:485–501. - PubMed
    1. Mikesch JH, Kuhlmann M, Demant A, Krug U, Thoennissen GB, Schmidt E, et al. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: A retrospective evaluation of parallel patient cohorts of one center. Ann Hematol. 2013;92:1041–8. - PubMed
    1. Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma. Ann Oncol. 2006;17(Suppl 4):iv25–30. - PubMed
    1. Kim MK, Kim S, Lee SS, Sym SJ, Lee DH, Kim SW, et al. Rituximab-ESHAP as a mobilization regimen for relapsed or refractory B-cell lymphomas: A comparison with ESHAP. Transfusion. 2007;47:1447–54. - PubMed

Publication types